Distribution of IL28b gene polymorphisms in a cohort of HIV/HCV coinfected patients. IL 28b polymorphisms association.

MONZANI C; BASTON M; ALOISI N; CORTI M; DE TEZANOS PINTO; PÉREZ BIANCO R; BRACCO MM; BARÉ P

Congreso; XXX International congress of the World Federation of Hemophilia; 2012

IL 28b CC genotype is a strong predictor of virological response to therapy in HIV/HCV coinfected patients but it was also found to be associated to more rapid progression to HCV related fibrosis. In consequence, in this group, the access to HCV treatment should be of utmost importance. CCR5 polymorphism in HIV coreceptor could be also of importance defining disease progression. The distribution of IL28b polymorphisms (locus rs12979860) was analyzed in parallel with clinical, immunological and virological markers in a group of 38 HIV/HCV coinfected hemophilic patients. CCR5 alleles were also characterized to find association to progression. Different parameters like age, HIV and HCV viral loads, hepatic enzymes (AST, ALT, GGT, ALP), CD4, CD8 and platelet counts, APRI index (AST platelet ratio index) were evaluated as surrogate clinical progression markers. To compare groups, the results were analyzed with Student t tests or Mann Whitney depending on their distribution. Chi square or Fisher tests were used for qualitative analysis. In our cohort, IL 28b genotypes were distributed as follows (n=38): 53% CC, 34% CT and 13% TT, similar to our control population (n=23). None of the parameters showed statistically significant differences between groups. Altered values were similarly distributed in both groups.